79 related articles for article (PubMed ID: 19962892)
1. Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration.
Hu B; Bernotas R; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wilhelmsson A; Nambi P; Evans M; Wrobel J
Bioorg Med Chem Lett; 2010 Jan; 20(2):689-93. PubMed ID: 19962892
[TBL] [Abstract][Full Text] [Related]
2. 4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists.
Bernotas RC; Singhaus RR; Kaufman DH; Travins JM; Ullrich JW; Unwalla R; Quinet E; Evans M; Nambi P; Olland A; Kauppi B; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem Lett; 2010 Jan; 20(1):209-12. PubMed ID: 19932617
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists.
Ullrich JW; Morris R; Bernotas RC; Travins JM; Jetter J; Unwalla R; Quinet E; Nambi P; Feingold I; Huselton C; Enroth C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem Lett; 2010 May; 20(9):2903-7. PubMed ID: 20382019
[TBL] [Abstract][Full Text] [Related]
4. 3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists.
Singhaus RR; Bernotas RC; Steffan R; Matelan E; Quinet E; Nambi P; Feingold I; Huselton C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem Lett; 2010 Jan; 20(2):521-5. PubMed ID: 20005711
[TBL] [Abstract][Full Text] [Related]
5. Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta.
Hu B; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wihelmsson A; Nambi P; Wrobel J
Bioorg Med Chem; 2009 May; 17(10):3519-27. PubMed ID: 19394832
[TBL] [Abstract][Full Text] [Related]
6. 1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor agonists.
Travins JM; Bernotas RC; Kaufman DH; Quinet E; Nambi P; Feingold I; Huselton C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem Lett; 2010 Jan; 20(2):526-30. PubMed ID: 20006495
[TBL] [Abstract][Full Text] [Related]
7. Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist.
Hu B; Unwalla RJ; Goljer I; Jetter JW; Quinet EM; Berrodin TJ; Basso MD; Feingold IB; Nilsson AG; Wilhelmsson A; Evans MJ; Wrobel JE
J Med Chem; 2010 Apr; 53(8):3296-304. PubMed ID: 20350005
[TBL] [Abstract][Full Text] [Related]
8. Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRβ.
Kick E; Martin R; Xie Y; Flatt B; Schweiger E; Wang TL; Busch B; Nyman M; Gu XH; Yan G; Wagner B; Nanao M; Nguyen L; Stout T; Plonowski A; Schulman I; Ostrowski J; Kirchgessner T; Wexler R; Mohan R
Bioorg Med Chem Lett; 2015 Jan; 25(2):372-7. PubMed ID: 25435151
[TBL] [Abstract][Full Text] [Related]
9. Biarylether amide quinolines as liver X receptor agonists.
Bernotas RC; Singhaus RR; Kaufman DH; Ullrich J; Fletcher H; Quinet E; Nambi P; Unwalla R; Wilhelmsson A; Goos-Nilsson A; Farnegardh M; Wrobel J
Bioorg Med Chem; 2009 Feb; 17(4):1663-70. PubMed ID: 19162487
[TBL] [Abstract][Full Text] [Related]
10. 4-(3-aryloxyaryl)quinoline alcohols are liver X receptor agonists.
Bernotas RC; Kaufman DH; Singhaus RR; Ullrich J; Unwalla R; Quinet E; Nambi P; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem; 2009 Dec; 17(23):8086-92. PubMed ID: 19853462
[TBL] [Abstract][Full Text] [Related]
11. Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis.
Hu B; Collini M; Unwalla R; Miller C; Singhaus R; Quinet E; Savio D; Halpern A; Basso M; Keith J; Clerin V; Chen L; Resmini C; Liu QY; Feingold I; Huselton C; Azam F; Farnegardh M; Enroth C; Bonn T; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
J Med Chem; 2006 Oct; 49(21):6151-4. PubMed ID: 17034119
[TBL] [Abstract][Full Text] [Related]
12. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.
Quinet EM; Savio DA; Halpern AR; Chen L; Schuster GU; Gustafsson JA; Basso MD; Nambi P
Mol Pharmacol; 2006 Oct; 70(4):1340-9. PubMed ID: 16825483
[TBL] [Abstract][Full Text] [Related]
13. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells.
DiBlasio-Smith EA; Arai M; Quinet EM; Evans MJ; Kornaga T; Basso MD; Chen L; Feingold I; Halpern AR; Liu QY; Nambi P; Savio D; Wang S; Mounts WM; Isler JA; Slager AM; Burczynski ME; Dorner AJ; LaVallie ER
J Transl Med; 2008 Oct; 6():59. PubMed ID: 18925943
[TBL] [Abstract][Full Text] [Related]
14. N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta.
Molteni V; Li X; Nabakka J; Liang F; Wityak J; Koder A; Vargas L; Romeo R; Mitro N; Mak PA; Seidel HM; Haslam JA; Chow D; Tuntland T; Spalding TA; Brock A; Bradley M; Castrillo A; Tontonoz P; Saez E
J Med Chem; 2007 Aug; 50(17):4255-9. PubMed ID: 17665897
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of a novel liver X receptor agonist with partial LXRα activity and a favorable window in nonhuman primates.
Kirchgessner TG; Martin R; Sleph P; Grimm D; Liu X; Lupisella J; Smalley J; Narayanan R; Xie Y; Ostrowski J; Cantor GH; Mohan R; Kick E
J Pharmacol Exp Ther; 2015 Feb; 352(2):305-14. PubMed ID: 25467132
[TBL] [Abstract][Full Text] [Related]
16. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype.
Lund EG; Peterson LB; Adams AD; Lam MH; Burton CA; Chin J; Guo Q; Huang S; Latham M; Lopez JC; Menke JG; Milot DP; Mitnaul LJ; Rex-Rabe SE; Rosa RL; Tian JY; Wright SD; Sparrow CP
Biochem Pharmacol; 2006 Feb; 71(4):453-63. PubMed ID: 16325781
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptor agonists with selectivity for LXRbeta; N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides.
Swahn BM; Macsari I; Viklund J; Ohberg L; Sjödin J; Neelissen J; Lindquist J
Bioorg Med Chem Lett; 2009 Apr; 19(7):2009-12. PubMed ID: 19264481
[TBL] [Abstract][Full Text] [Related]
18. Propofol up-regulates expression of ABCA1, ABCG1, and SR-B1 through the PPARγ/LXRα signaling pathway in THP-1 macrophage-derived foam cells.
Ma X; Li SF; Qin ZS; Ye J; Zhao ZL; Fang HH; Yao ZW; Gu MN; Hu YW
Cardiovasc Pathol; 2015; 24(4):230-5. PubMed ID: 25600616
[TBL] [Abstract][Full Text] [Related]
19. Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity.
Hu B; Quinet E; Unwalla R; Collini M; Jetter J; Dooley R; Andraka D; Nogle L; Savio D; Halpern A; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
Bioorg Med Chem Lett; 2008 Jan; 18(1):54-9. PubMed ID: 18023179
[TBL] [Abstract][Full Text] [Related]
20. Ligation of RAGE with ligand S100B attenuates ABCA1 expression in monocytes.
Kumar P; Raghavan S; Shanmugam G; Shanmugam N
Metabolism; 2013 Aug; 62(8):1149-58. PubMed ID: 23523156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
